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Comprehensive Association Study of Type 2 Diabetes and
Related Quantitative Traits With 222 Candidate Genes
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William L. Duren,2 Peter S. Chines,3 Narisu Narisu,3 Lori L. Bonnycastle,3 Jingchun Luo,4
Maurine Tong,3 Andrew G. Sprau,3 Elizabeth W. Pugh,5 Kimberly F. Doheny,5 Timo T. Valle,6
Gonc¸alo R. Abecasis,2 Jaakko Tuomilehto,6,7,8 Richard N. Bergman,9 Francis S. Collins,3
Michael Boehnke,2 and Karen L. Mohlke1
OBJECTIVE—Type 2 diabetes is a common complex disorder
with environmental and genetic components. We used a candi-
date gene–based approach to identify single nucleotide polymor-
phism (SNP) variants in 222 candidate genes that influence
susceptibility to type 2 diabetes.
RESEARCH DESIGN AND METHODS—In a case-control
study of 1,161 type 2 diabetic subjects and 1,174 control Finns
who are normal glucose tolerant, we genotyped 3,531 tagSNPs
and annotation-based SNPs and imputed an additional 7,498
SNPs, providing 99.9% coverage of common HapMap variants in
the 222 candidate genes. Selected SNPs were genotyped in an
additional 1,211 type 2 diabetic case subjects and 1,259 control
subjects who are normal glucose tolerant, also from Finland.
RESULTS—Using SNP- and gene-based analysis methods, we
replicated previously reported SNP-type 2 diabetes associations
in PPARG, KCNJ11, and SLC2A2; identified significant SNPs in
genes with previously reported associations (ENPP1 [rs2021966,
P 0.00026] and NRF1 [rs1882095, P 0.00096]); and implicated
novel genes, including RAPGEF1 (rs4740283, P  0.00013) and
TP53 (rs1042522, Arg72Pro, P  0.00086), in type 2 diabetes
susceptibility.
CONCLUSIONS—Our study provides an effective gene-based
approach to association study design and analysis. One or more
of the newly implicated genes may contribute to type 2 diabetes
pathogenesis. Analysis of additional samples will be necessary to
determine their effect on susceptibility. Diabetes 57:3136–
3144, 2008
Type 2 diabetes is a metabolic disorder character-ized by insulin resistance and pancreatic -celldysfunction and is a leading cause of morbidityand mortality in the U.S. and worldwide. The
incidence of type 2 diabetes is rapidly increasing, with 1.6
million new cases of diabetes diagnosed in individuals
aged 20 years in the U.S. in 2007 (available at http://
www.diabetes.niddk.nih.gov/dm/pubs/statistics/). While
environmental factors play a major role in predisposition
to type 2 diabetes, substantial evidence supports the
influence of genetic factors on disease susceptibility. For
example, the twin concordance rate is an estimated 34%
for monozygotic twins and 16% for dizygotic twins (1).
However, the underlying genetic variants are just begin-
ning to be identified (2).
Numerous published reports (3–5) have identified asso-
ciation between type 2 diabetes and common genetic
variants in human populations; however, until very re-
cently, variants in only a few genes have been consistently
replicated across populations and with large sample sizes.
Among these are the Pro12Ala (rs1801282) variant in
peroxisome proliferator–activated receptor  (PPARG)
(6), the Glu23Lys (rs5210) variant in the potassium chan-
nel gene KCNJ11 (7), and several variants in the Wnt-
receptor signaling pathway member TCF7L2 (8).
Recent genome-wide studies have implicated many pre-
viously unreported genes in type 2 diabetes susceptibility.
The first reported genome-wide association (GWA) scan
implicated variants at five susceptibility loci that include
TCF7L2 and novel loci near the genes SLC30A8, IDE-
KIF11-HHEX, LOC387761, and EXT-ALX4 (9). Three
companion GWA studies (10–12), including one by our
group, replicated evidence for PPARG, KCNJ11, TCF7L2,
SLC30A8, and IDE-KIF11-HHEX and provided new evi-
dence for CDKAL1, CDKN2A-CDKN2B, IGF2BP2, FTO,
and a region of chromosome 11 with no annotated genes.
Additional GWA studies (13–18) provided additional evi-
dence for TCF7L2, CDKAL1, and SLC30A8. The candidate
genes WFS1 (19) and TCF2 (20,21) have also been con-
firmed in large samples, bringing the current list of type 2
diabetes susceptibility loci to at least 10. The recent
discovery of these loci still explains only a small fraction
(2.3%) of the overall risk of type 2 diabetes (12). There-
fore, novel susceptibility genes remain to be identified
through increasingly comprehensive analyses of both in-
dividual genes and the entire genome.
The Finland-U.S. Investigation of Type 2 Diabetes Ge-
netics (FUSION) study aims to identify variants influenc-
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ing susceptibility to type 2 diabetes and related
quantitative traits in the Finnish population (22). FUSION
has previously identified modest type 2 diabetes associa-
tion in Finns with variants in HNF4A (23); four genes
known to cause maturity-onset diabetes of the young
(5,23,24); PPARG, KCNJ11, ENPP1, SLC2A2, PCK1, TNF,
IL6 (5), and TCF7L2 (25); and the loci identified in the
GWA studies.
As a complementary approach to GWA studies, which
are conducted without a priori biological hypotheses, we
sought to perform an in-depth analysis of 200 genes
likely to influence susceptibility to type 2 diabetes and
quantitative trait variation that we selected by applying
CandidAtE Search And Rank (CAESAR), a text- and data-
mining algorithm (26). We aimed to analyze the full
spectrum of HapMap-based common variation in each of
these candidate genes. The combination of high through-
put genotyping, linkage disequilibrium (LD) information
from HapMap (27), the ability to impute ungenotyped
variants (28), and the improved functional annotation of
the genome makes in-depth candidate gene–based associ-
ation analysis possible.
RESEARCH DESIGN AND METHODS
The stage 1 sample set consisted of 2,335 Finnish individuals from the FUSION
(22,29) and Finrisk 2002 (30) studies (Table 1) (online appendix Table 1A
[available at http://dx.doi.org/10.2337/db07–1731]). The sample included 1,161
individuals with type 2 diabetes and 1,174 control subjects with normal
glucose tolerance. Diabetes was defined according to 1999 World Health
Organization criteria (fasting plasma glucose concentration 7.0 mmol/l or
2-h plasma glucose concentration 11.1 mmol/l), by report of diabetes
medication use, or based on medical record review. Normal glucose tolerance
was defined as having fasting glucose 6.1 mmol/l and 2-h glucose 7.8
mmol/l. A total of 120 FUSION offspring with genotyped parents were
included for quantitative trait analysis; all offspring had normal glucose
tolerance except one type 2 diabetic individual who was included in the case
sample.
Stage 2 consisted of 2,473 Finnish individuals (Table 1) (online appendix
Table 1B) and included 1,215 individuals with type 2 diabetes and 1,258
control subjects with normal glucose tolerance (10). A total of 56 duplicate
samples were used for quality control. The sample sets are identical to those
used in the FUSION GWA study (10). Study protocols were approved by local
ethics committees and/or institutional review boards, and informed consent
was obtained from all study participants.
Gene selection. A total of 222 candidate genes were selected for study using
two strategies. Two hundred and seventeen candidate genes were selected
using CAESAR, an algorithm that prioritizes candidate genes for complex
human traits based on trait-relevant functional annotation (26). Given a
trait-relevant input text, CAESAR 1) uses text mining to extract gene symbols
and to find and rank terms present in four biomedical ontologies (gene
ontology biological process [31], gene ontology molecular function [31], eVOC
anatomy [32], and mammalian phenotype ontology [33]) based on frequency of
occurrence, 2) uses the ranked ontology terms and extracted gene symbols to
data mine several public databases for human genes annotated with the
ontology terms or extracted gene symbols, and 3) integrates the resulting gene
annotation lists to provide a combined score and rank for each gene. Details
of gene selection using custom parameters for CAESAR are provided in the
online appendix.
Five genes were not ranked high enough to have been included using
CAESAR. ENPP1, HFE, WFS1, and ZNHIT3 were included because each had
one or more single nucleotide polymorphisms (SNPs) associated with type 2
diabetes (P  0.1) in a prior study of a subset of FUSION samples (6) (C.J.W.,
L.L.B., M.B., and K.L.M., unpublished data); in addition, ENPP1 and WFS1 had
been previously studied as type 2 diabetes candidate genes. CAPN10 was
included because it had been previously studied by FUSION (34) and others
(35,36).
SNP selection. We defined the “transcribed region” of each of the 222
candidate genes as the sequence including the first exon of any transcribed
isoform through the last exon of any transcribed isoform, and we aimed to
capture variation up to 10 kb upstream and 5 kb downstream of the
transcribed region (10 kb/5 kb). In this process, we allowed SNPs to be
located as far as 50 kb upstream and 50 kb downstream (50 kb/50 kb) of
the transcribed region if they tagged a 10-kb/5-kb SNP at r 2  0.8.
Briefly, 3,531 SNPs were selected for stage 1 genotyping as follows. We
selected SNPs from the Illumina Infinium II HumanHap300 BeadChip that
tagged one or more 10-kb/5-kb SNPs (r 2  0.8). Then, to evaluate each
gene region more comprehensively, we selected 1) additional tagSNPs and 2)
functionally annotated non-HapMap SNPs for genotyping on an Illumina
GoldenGate panel. We also included eight SNPs that had been previously
genotyped in candidate gene studies on a smaller subset of FUSION samples
(5). Additional details of SNP selection are provided in the online appendix.
Genotyping. Stage 1 genotyping of 317,503 SNPs was performed at the Center
for Inherited Disease Research on the HumanHap300 BeadChip using the
Illumina Infinium II assay protocol (10), and 1,527 SNPs were genotyped in
partnership with the Mammalian Genotyping Core at the University of North
Carolina using the Illumina GoldenGate assay. We performed additional
genotyping for eight previously reported SNPs (5) using the Sequenom
homogeneous MassEXTEND assay and four imputed SNPs using Applied
Biosystems TaqMan allelic discrimination assays. There was a genotype
consistency rate of 99.88% between each platform, using 79 duplicate
samples. Stage 2 genotyping of 31 SNPs was performed using the homoge-
neous MassEXTEND assay; there was a genotype consistency rate of 100%,
using 56 duplicate samples. SNP and sample success rates and quality-control
filters are described in the online appendix.
Imputation. We used MACH, a computationally efficient hidden Markov
model–based algorithm (available at http://www.sph.umich.edu/csg/abecasis/
MACH/) (28), to impute genotypes in FUSION samples for 7,498 common
(minor allele frequency [MAF]  0.05) HapMap SNPs present in the target
regions but not genotyped in our study. To improve the quality of imputation
near the ends of the target regions, we used at least 1 Mb of flanking genotype
information to impute SNPs in target regions.
Coverage of HapMap SNPs. Coverage was calculated as the percentage of
all common (MAF 0.05) HapMap Release 21 CEU SNPs in the10-kb/5-kb
gene regions that are tagged by a genotyped SNP at an r 2 threshold of at
least 0.8.
Type 2 diabetes association analysis. Genotyped SNPs were tested for type
2 diabetes association using logistic regression under additive (Padd), domi-
nant, and recessive genetic models with adjustment for 5-year age category,
sex, and birth province. Imputed SNPs were tested for type 2 diabetes
association using logistic regression under an additive model (Pimpute), with
TABLE 1
Characteristics of the stage 1 and 2 case and control samples
Stage 1 Stage 2
Case
subjects
Control
subjects
Case
subjects
Control
subjects
n 1,161 1,174 1,215 1,258
Male subjects 653 574 724 768
Female subjects 508 600 491 490
Age of diagnosis (years) 53.0	 12.0 N/A 56.0	 12.0 N/A
Study age (years) 63.4	 11.2 64	 11.7 60.0	 11.5 59.0	 10.6
BMI (kg/m2) 29.8	 6.1 26.8	 5.0 30.1	 6.7 26.4	 4.9
Fasting glucose (mmol/l) 8.4	 3.9 5.4	 0.7 7.2	 2.1* 5.4	 0.6†
Data are medians	 interquartile ranges unless otherwise indicated. *n  204 and †n  583 values converted from whole blood to plasma
glucose equivalent using a prediction equation from the European Diabetes Epidemiology Group, of which †n  262 fasted 8 h.
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the expected allele count in place of the allele count and adjusted for the same
covariates. This approach takes into account the degree of uncertainty of
genotype imputation in a computationally efficient manner by replacing allele
counts (0, 1, and 2) at the marker locus by predicted allele counts based on
estimated probabilities of 0, 1, or 2 copies of a SNP allele (available at
http://www.sph.umich.edu/csg/abecasis/MACH/) (28).
We accounted for carrying out multiple correlated tests using the P value
adjusted for correlated tests (PACT) method (37). The PACT method was used
to correct the minimum P value among 1) tests of three genetic models for a
single SNP (PSNP) and 2) multiple SNPs and models across a gene region
(Pgene). Details are provided in the online appendix. We determined the
independence of significant association signals in genes by including one SNP
as a covariate in logistic regression and reassessing the evidence for associ-
ation with the other SNPs.
Quantitative trait analysis. We tested all genotyped and imputed SNPs for
association with 20 type 2 diabetes–related quantitative traits, including, in
control subjects only, fasting insulin, fasting glucose, homeostasis model
adjustment, and fasting free fatty acids; and, in all samples, BMI, weight, waist
circumference, hip circumference, waist-to-hip ratio, waist-to-height2 ratio,
total cholesterol, HDL cholesterol, LDL cholesterol, triglyceride level, choles-
terol-to-HDL ratio, triglyceride-to-HDL ratio, diastolic blood pressure, systolic
blood pressure, pulse, and pulse pressure.
For case and control subjects separately, we regressed the quantitative
trait variables on age, age2, sex, birth province, and study indicator and
transformed the residuals of each quantitative trait to approximate normality
using inverse normal scores, which involves ranking the residual values and
then converting these to z-scores according to quantiles of the standard
normal distribution. We then carried out association analysis on the residuals.
To allow for relatedness, regression coefficients were estimated in the context
of a variance component model that also accounted for background polygenic
effects (38). For genotyped SNPs, we tested for association using the residuals
under an additive model. For imputed SNPs, we tested for association using
the residuals and the expected allele count in place of the allele count under
an additive model. Case and control results were combined using meta-
analysis, as described in the online appendix.
RESULTS
We studied 222 candidate genes for type 2 diabetes asso-
ciation in our stage 1 sample of 1,161 type 2 diabetic case
subjects and 1,174 control subjects with normal glucose
tolerance from the FUSION study (Table 1). Of 10,762
target HapMap SNPs (MAF  0.05) in the 10-kb/5-kb
gene regions, 3,531 genotyped SNPs cover 10,299 (95.7%)
SNPs at an r 2 threshold of 0.8. This represents an improve-
ment over the genome-wide HumanHap300 genotyped
SNPs, which alone cover 79.0% of the target SNPs at r 2 
0.8 (Table 2). A total of 3,187 of 3,531 genotyped SNPs are
located in the 10-kb/5-kb regions. Of the remaining
7,575 ungenotyped target SNPs, 7,498 were successfully
imputed. Altogether, 99.9% of all target variation was
genotyped, imputed, or tagged (r 2  0.8) by an analyzed
SNP.
We evaluated the significance of genotyped SNPs in
each gene region after correcting for multiple SNPs
tested while accounting for the LD between SNPs,
designated Pgene (37). Given six pairs of adjacent genes
(see online appendix), we analyzed 216 distinct gene
regions for type 2 diabetes association (online appendix
Table 2). SNPs in four gene regions (rs11183212 in
ARID2 [Pgene  0.0029], rs2235718 in FOXC1 [Pgene 
0.0028], rs8069976 in SOCS3 [Pgene  0.0037], and
rs222852 in SLC2A4 [Pgene  0.0024]) were significantly
associated with type 2 diabetes at Pgene  0.005, al-
though no Pgene result reached a study-wide significance
of 0.00023, a threshold determined using a Bonferroni
correction. SNPs in 19 genes were significant at Pgene 
0.05, including SNPs in three genes previously impli-
cated in type 2 diabetes susceptibility in FUSION (5)
(Table 3). There was an excess of significant Pgene
results at both thresholds (4 at Pgene  0.005 [P  0.024];
19 at Pgene  0.05 [P  0.013]). The excess of significant
results at Pgene  0.005 is maintained after excluding 1)
seven genes showing prior evidence of association with
any SNP in FUSION samples (P  0.022) or 2) five genes
not selected by CAESAR (P  0.022), as no excluded
genes were significant at that threshold (see online
appendix).
To evaluate all 3,531 genotyped SNPs (online appendix
Table 3), we permuted the case/control status to estimate
whether an excess of significant results was observed. A
total of 214 SNPs showed significant type 2 diabetes
association at a PSNP threshold of 0.05, and, of these, 26
were associated at a PSNP threshold of 0.005 (Table 4).
There was modest, but not significant, excess at both of
these PSNP thresholds (observed  214, expected  183.3,
P  0.09 and observed  26, expected  18.9, P  0.12,
respectively). The most significant PSNP value of 3.6 

104 was observed for rs11183212, an intronic SNP in the
ARID2 gene, but when compared with an empirical distri-
bution of the most significant P values, this SNP does not
reach a study-wide significance threshold of 6.3 
 105,
based on 1,000 permutations. In the combined stage 1 and
2 sample, we have 99% power (80% in stage 1 alone) to
detect the most strongly associated previously observed
type 2 diabetes SNP, rs7903146 in TCF7L2 (9–12), at a
study-wide significance level, and substantially less power
to detect type 2 diabetes–associated SNPs with smaller
effect sizes.
Nineteen of 216 gene regions have at least one SNP
significantly associated with type 2 diabetes at PSNP 
0.005; among these, Pro12Ala (rs1801282) in PPARG
(PSNP  0.0025) was the only SNP that matched or was
in high LD (r 2  0.8) with a previously reported variant,
given the available HapMap LD information. Imputation
identified 421 additional SNPs in 59 genes significantly
associated with type 2 diabetes (Pimpute  0.05) (online
appendix Table 4), including SNPs in 10 genes that did
not contain a significant genotyped SNP (PSNP  0.05).
We genotyped four of these initially imputed SNPs that
were both significantly associated with type 2 diabetes
(Pimpute  0.05) and for which the imputation-based P
value was at least five times more significant than that
for any nearby genotyped SNP; three of four SNPs had
TABLE 2
Coverage of 10,762 HapMap SNPs (MAF  0.05)* within 10
kb/5 kb of 222 candidate genes
SNPs 10 kb/5 kb of gene
Number
of SNPs
analyzed†
Number
captured‡
Percent
captured‡
SNPs genotyped on GWA
panel only 2,150 8,507 79.04
All 3,531 genotyped SNPs 3,531 10,299 95.74
Genotyped and imputed
SNPs from GWA panel
only 10,596 10,647 98.93
All 3,531 genotyped and
7,498 imputed SNPs 11,029 10,752§ 99.91
*MAF  0.05 in HapMap CEU. †Genotyped SNPs are located within
50 kb/50 kb of a gene but may not be within 10 kb/5 kb of a
gene. Imputed SNPs are all located within 10 kb/5 kb of a gene.
‡HapMap SNPs genotyped, imputed, or tagged (r2  0.8) by a
genotyped SNP. §A total of 10,752 includes 3,187 genotyped SNPs,
7,498 imputed SNPs, and 67 SNPs tagged (r2  0.8) by a genotyped
SNP.
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highly concordant imputed and genotyped P values
(online appendix Table 5).
We selected for follow-up genotyping in stage 2 samples
24 SNPs that were either significant at PSNP  0.005 or, if
a nonsynonymous variant, significant at PSNP  0.01
(Table 1). The most significant SNPs in the combined stage
1 and 2 samples were rs4740283 in RAPGEF1 (PSNP 
0.00013), rs2021966 in ENPP1 (PSNP  0.00026), Arg72Pro
(rs1042522) in TP53 (PSNP  0.00086), and rs1882095 in
NRF1 (PSNP  0.00096). In total, 16 SNPs were significant
at PSNP  0.05 in the combined stage 1 and 2 samples
(Table 4).
To evaluate the effect of BMI, we included BMI as an
additional covariate in an analysis of the additive model
for all genotyped and imputed SNPs. Of 11 SNPs originally
significant at Padd  0.001, all P values were similar (Padd 
0.01) after adjustment (online appendix Table 6A). Of 16
SNPs significant at Padd  0.001 after adjustment, two
SNPs had notably less significant P values (Padd  0.01)
before adjustment; both SNPs are located at the
TRIP10/C3 locus (online appendix Table 6B).
Four genotyped and 30 imputed SNPs were strongly
associated (P  0.0001) with one or more of 20 quanti-
tative traits after combining case and control subjects
by meta-analysis (see RESEARCH DESIGN AND METHODS) (Ta-
ble 5 and online appendix Table 7). Variants in APOE
and PPARA showed strong evidence of association with
serum lipid levels, confirming previous reports (39,40).
Strong novel associations (P  1 
 105) were observed
for rs4912407 in PRKAA2 with triglyceride level (P 
3.68 
 106), rs10517844 in CPE with HDL level (P 
2.07 
 105), and rs4689388 in WFS1 with LDL level
(P  5.30 
 105). We followed-up genotyped SNPs
significantly associated (P  0.0001) with one or more
quantitative traits by genotyping the stage 2 samples. No
SNP showed study-wide significance in the combined
stage 1 and 2 samples (Table 5).
DISCUSSION
In this study, we evaluated the evidence for type 2 diabetes
association for SNPs in 222 candidate genes and provided
a framework for thorough analysis of association of com-
mon variation to disease using gene-based functional
annotation, HapMap LD information, and imputation of
genotypes. This framework could be used in the context of
a GWA study or an independent investigation of candidate
genes. We replicated previous type 2 diabetes association
with SNPs in PPARG, KCNJ11, and SLC2A2; identified
significant SNPs in genes previously implicated in type 2
diabetes risk, NRF1 and ENPP1; and identified additional
genes that may influence susceptibility to type 2 diabetes
and related quantitative traits, including RAPGEF1 and
TP53. While some of the genes may be significant by
chance, one or more may represent true susceptibility
genes. We expect that true susceptibility genes identified
in our sample set will, in many cases, be shared in
additional populations, as the FUSION GWA study identi-
fied many of the same risk alleles as other GWA studies of
European populations (9–13).
To assess the role of 222 genes in susceptibility to type
2 diabetes, we attempted to assess complete coverage of
common (MAF  0.05) SNPs in the HapMap CEU data-
base. The coverage of common HapMap CEU SNPs across
all 222 candidate genes using genotyped SNPs was 95.7%,
a 16.7% percent improvement over the coverage of 79.0%
based on the Illumina HumanHap300 genome-wide panel
(Table 2). HapMap provides excellent coverage of com-
mon variation in European samples; however, there are
additional non-HapMap SNPs in these gene regions (27).
Of 122 genotyped SNPs not in HapMap, 10 were not tagged
at an r 2 threshold of 0.8 by a HapMap SNP, indicating that
some of the non-HapMap variation is better covered in our
study than the GWA study panel.
Our SNP that is most strongly associated with type 2
TABLE 3
Gene regions (10 kb/5 kb) associated with type 2 diabetes (Pgene  0.05) in stage 1 samples
Gene
symbol Chromosome
Start position*
(bp)
End position*
(bp)
Coverage
(%)† SNP‡ Pgene
SLC2A4 17 7,125,835 7,131,125 90.0 rs222852 0.0024
FOXC1 6 1,555,680 1,557,341 100.0 rs2235718 0.0028
ARID2 12 44,409,887 44,588,086 97.8 rs11183212 0.0029
SOCS3 17 73,864,459 73,867,753 100.0 rs8069976 0.0037
FOXC2 16 85,158,443 85,159,948 100.0 rs4843165 0.012
ENPP1§¶ 6 132,170,853 132,254,043 94.8 rs9402346 0.014
PRKAA2 1 56,823,041 56,886,142 90.0 rs11206883 0.014
JAK3 19 17,797,961 17,819,800 85.7 rs11888 0.016
CBLB 3 106,859,799 107,070,577 98.8 rs17280845 0.017
SLC2A2§ 3 172,196,839 172,227,470 100.0 rs10513684 0.023
PRKAR2B 7 106,279,129 106,396,206 97.0 rs2395836 0.027
EDF1 9 137,032,408 137,036,575 100.0 rs3739942 0.029
PCK2 14 23,633,323 23,643,177 100.0 rs2759407 0.034
PRKAG3 2 219,512,611 219,522,017 100.0 rs6436094 0.037
MECR 1 29,340,001 29,378,070 87.1 rs10915239 0.038
RXRA 9 134,519,422 134,558,376 85.7 rs3118526 0.040
PPARGC1A 4 23,469,914 23,567,969 94.4 rs2970871 0.041
PPARG§ 3 12,304,359 12,450,840 99.1 rs1801282 0.042
NR1I3 1 158,012,528 158,021,028 100.0 rs2502807 0.049
*Start and end positions of transcribed region (see research design and methods). Positions based on hg17. †Percentage of common (MAF
0.05) SNPs within10 kb/5 kb of a gene and captured at r2 of at least 0.8. ‡SNP with minimum P value in given gene used to calculate Pgene
value (see RESEARCH DESIGN AND METHODS). §Gene has previous evidence of association in FUSION. ¶Selected for study only based on previous
evidence of association in FUSION.
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diabetes in the stage 1 and 2 samples was SNP rs4740283
(PSNP 0.00013), located 4 kb downstream of Rap guanine
nucleotide exchange factor 1 (RAPGEF1). RAPGEF1 is a
ubiquitously expressed gene involved in insulin signaling
(41) and Ras-mediated tumor suppression (42). rs4740283
is in strong LD with SNPs in the coding region and may
affect either a regulatory element or protein function.
Variation in this gene may contribute to susceptibility
through reduced ability of peripheral tissues to absorb
glucose in response to insulin.
The second strongest-associated SNP in the stage 1 and 2
samples was Arg72Pro in TP53 (rs1042522, PSNP  0.00086),
which was originally identified by imputation, subsequently
genotyped, and not well tagged by any originally genotyped
SNP (maximum r 2 0.27 with rs2909430). TP53 encodes the
tumor suppressor protein p53, and the Arg72Pro variant has
a functional role in the efficiency of p53 in inducing apopto-
sis, possibly through reduced localization to the mitochon-
dria (43). The risk allele Arg72 has higher apoptotic potential,
which is consistent with a possible link between increased
pancreatic -cell apoptosis, impaired insulin secretion, and
type 2 diabetes.
We observed significant association with SNPs in two
genes previously implicated in type 2 diabetes susceptibil-
ity, nuclear respiratory factor 1 (NRF1) and the insulin-
dependent facilitated glucose transporter SLC2A2. NRF1
helps regulate mitochondrial transcription and oxidative
phosphorylation (44), which has a known role in insulin
resistance, and the associated NRF1 variant, rs1882095, is
located 1 kb downstream of the gene and not in modest LD
(r 2  0.6) with any HapMap SNP. In SLC2A2 we found
supporting evidence in stage 1 for the nonsynonymous
variant Thr110Ile (rs5400) (PSNP  0.0065), as well as a
previously unreported variant, rs10513684 (PSNP 
0.0046). The rs10513684 signal became slightly more sig-
nificant after stage 2 genotyping (PSNP 0.0023); however,
the signal was attenuated (P  0.18) after inclusion of
Thr110Ile in the analysis.
Among the most significant type 2 diabetes–associated
SNPs is rs2021966 in ENPP1 (PSNP  0.00026). SNPs in
high LD with rs2021966 are located in intron 1, in a region
of strong multispecies conservation containing a pseudo-
gene but no known transcripts. Previous studies of ENPP1
have reported associations with rs1044498 and with a
related three-SNP haplotype (rs1044498, rs1799774, and
rs7754561) and support a modest role in type 2 diabetes
susceptibility, possibly acting through obesity (45). In our
study, rs1044498 (PSNP  0.16) and rs7754859 (PSNP 
0.18, r 2  1 with rs7754561) were not significantly associ-
ated with type 2 diabetes (rs1799774 was not tested). The
newly identified variants are in very low LD with rs1044498
(r 2  0.05).
Although we observed significant quantitative trait as-
sociations in previously implicated genes (APOE and
PPARA with serum lipid levels), no quantitative trait
associations became more significant after addition of
stage 2 samples (Table 5). This is likely due in part to the
small number of SNPs selected for follow-up. Stage 2
genotyping of SNPs less significant in stage 1 samples will
be necessary to establish whether any novel SNPs contrib-
ute to quantitative trait variability.
In any gene-based study, the definition of gene bound-
aries is critical but, by necessity, somewhat arbitrary.
We defined a gene region as 10 kb upstream of the first
known exon through 5 kb downstream of the last known
exon in an attempt to capture the majority of nearby
regulatory elements influencing a gene. Regulatory ele-
ments, however, can often be found up to several
hundred kilobases away from a gene (46). We evaluated
whether a broader definition of a gene had a substantial
effect on the Pgene results by testing extended gene
regions 50 kb upstream and 50 kb downstream of
transcribed regions and by including HumanHap300
SNPs from these regions in our analysis. Using the
extended gene boundaries, the insulin gene INS would
be the most significant gene in our study (Pgene 
0.0019), driven by SNP rs10743152 (PSNP  0.00015)
located 13 kb upstream of the first exon. Other genes
that had significant SNPs (Pgene  0.05) only in the
extended gene region were MAP2K1, CDK4, and IRF4.
Even using the narrow gene boundaries, several SNPs
in our study may influence expression or function of
other nearby or even more distant genes. Recent GWA
studies have confirmed novel susceptibility variants
TABLE 5
Quantitative trait association results for SNPs genotyped in FUSION stage 1 and 2 samples
SNP Gene Chromosome
Position
(bp)
Major/minor
allele Trait Samples*
Stage 1
P value†
Stage 2
P value†
Combined
P value‡
rs9615264 PPARA 22 44,953,108 G/A HDL level 4,682 1.06E-04 0.13 0.00013
rs10517844 CPE 4 166,691,996 T/C
Cholesterol-to
HDL ratio 4,682 4.00E-05 0.66 0.009
HDL level 4,682 2.07E-05 0.098 0.065
rs4689388 WFS1 4 6,388,128 A/G LDL level 4,067 5.30E-05 0.94 0.002
rs429358 APOE 19 50,103,781 T/C
Cholesterol-to
HDL ratio 2,327 1.78E-10 § —
LDL level 2,257 1.09E-06 § —
HDL level 2,327 2.36E-06 § —
Cholesterol level 2,327 1.51E-05 § —
rs4912407 PRKAA2 1 56,825,022 G/A Triglyceride level 2,339 3.68E-06 § —
Triglyceride-to
HDL ratio 2,339 2.77E-05 § —
*Number of samples corrected to an effective sample size considering the relatedness of some samples. †P value calculated under
additive model. ‡Stage 1 and 2 P values combined by meta-analysis (see RESEARCH DESIGN AND METHODS). §SNP was not successfully
genotyped in stage 2.
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downstream of HHEX, a gene selected for this study by
CAESAR (9 –12); the reported SNPs are located outside
of the narrow gene region (10 kb/5 kb) in a large LD
block that includes KIF11 and IDE, and we only de-
tected nominal significance in the narrow HHEX region
(PSNP  0.037 for rs12262390). For some genes, the
extent of LD surrounding significant SNPs implicates
flanking genes. For example, in ARID2, rs35115 (PSNP 
0.0067) is located in intron 7 but also tags the nonsyn-
onymous variant rs7315731 in SFRS2IP (r 2  0.93).
These examples demonstrate that defining a gene
boundary requires a balance between capturing all
possible SNPs influencing the gene and introducing
SNPs that may be more functionally relevant to other
genes. A more sophisticated approach to establish gene
boundaries that defines each gene boundary separately
by considering the genomic context around the gene
may be helpful in future gene-based approaches.
Gene-based approaches to interpreting the results of
candidate gene and even genome-wide association studies
are important because most variation influencing suscep-
tibility to type 2 diabetes and other common complex
traits is currently expected to be gene centric, although
the definition of a gene is constantly evolving. Detailed
coverage of the common variation in these genes repre-
sents a critical requirement for an effective and thorough
gene-based study. Here, we have identified genes signifi-
cantly associated with type 2 diabetes and related quanti-
tative traits that are attractive targets for future replication
studies. Confirmation in a larger sample set and meta-
analyses across studies will be important to help deter-
mine the role of these genes.
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